SLC2A4 and type 2 diabetes mellitus: Researches have shown [7, 8] that the LKB1–AMPK–GLUT4 signaling pathway could have abnormal expression in the skeletal muscle of patients with type 2 diabetes, consequently reducing the insulin sensitivity and increasing the blood glucose level [9, 10].